Swerdlow S, Campo E, Lee Harris N, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–11.
Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86:45–53.
Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16:161–70.
Ding J, Dirks WG, Ehrentraut S, et al. BCL6—regulated by AhR/ARNT and wild-type MEF2B—drives expression of germinal center markers MYBL1 and LMO2. Haematologica. 2015;100:801–9.
Ying CY, Dominguez-Sola D, Fabi M, et al. MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma. Nat Immunol. 2013;14:1084–92.
Basso K, Saito M, Sumazin P, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010;115:975–84.
Pon JR, Marra MA. MEF2 transcription factors: developmental regulators and emerging cancer genes. Oncotarget. 2016;7:2297–312.
Basso K, Brescia P, Schneider C, et al. MEF2B instructs germinal center development and acts as an oncogene in B cell lymphomagenesis. Chantilly, VA: ASH Meeting on Lymphoma Biology; 2018.
Pon JR, Wong J, Saberi S, et al. MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation. Nat Commun. 2015;6:7953.
Moore EM, Swerdlow SH, Gibson SE. Comparison of myocyte enhancer factor 2B versus other germinal center-associated antigens in the differential diagnosis of B-cell non-Hodgkin lymphomas. Am J Surg Pathol. 2018;42:342–50.
Krenács D, Borbényi Z, Bedekovics J, et al. Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas. Virchows Arch. 2015;467:345–55.
Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26:1383–90.
Yang Y, Shaffer AL, Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723–37.
Camicia R, Bachmann SB, Winkler HC, et al. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNÂ-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma. J Cell Sci. 2013;126:1969–80.
Hassan M, Mirmohammadsadegh A, Selimovic D, et al. Identification of functional genes during Fas-mediated apoptosis using a randomly fragmented cDNA library. Cell Mol Life Sci. 2005;62:2015–26.
Negi AK, Kansal S, Bhatnagar A, et al. Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis. Tumour Biol. 2013;34:3753–64.
El Jamal SM, Taylor EB, Abd Elmageed ZY, et al. Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways. Cell Div. 2016;11:11.
Selimovic D, Porzig BB, El-Khattouti A, et al. Bortezomib/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells. Cell Signal. 2013;25:308–18.
Selimovic D, Sprenger A, Hannig M, et al. Apoptosis related protein-1 triggers melanoma cell death via interaction with the juxtamembrane region of p75 neurotrophin receptor. J Cell Mol Med. 2012;16:349–61.
El-Khattouti A, Selimovic D, Hannig M, et al. Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-κB inhibition. J Cell Mol Med. 2016;20:266–86.
Hassan M, Selimovic D, Ghozlan H, et al. Induction of high-molecular-weight (HMW) tumor necrosis factor(TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-kappaB-dependent activation. Cell Signal. 2007;19:301–11.
Visco C, Li Y, Xu-Monette ZY, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia. 2012;26:2103–13.
Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214–7.
Saad AG, Grada Z, Bishop B, et al. nCounter NanoString Assay shows variable concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin. Appl Immunohistochem Mol Morphol 2018.
El Jamal SM, Yaseen AA, Alatassi H, et al. Strong NFκB expression is associated with high-grade dysplasia in barrett's esophagus. Appl Immunohistochem Mol Morphol. 2016;2:329–33.
Daems C, Martin LJ, Brousseau C, et al. MEF2 is restricted to the male gonad and regulates expression of the orphan nuclear receptor NR4A1. Mol Endocrinol. 2014;28:886–98.
McCarty KS, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716–21.
Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–807.
Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7:e51862.
Tzankov A, Zlobec I, Went P, et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma. 2010;51:199–212.
Williams PM, Li R, Johnson NA, et al. A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays. J Mol Diagn. 2010;12:680–6.
Shaknovich R, Geng H, Johnson NA, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 2010;116:e81–89.
Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.
Salaverria I, Philipp C, Oschlies I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011;118:139–47.
Kikuchi M, Miki T, Kumagai T, et al. Identification of negative regulatory regions within the first exon and intron of the BCL6 gene. Oncogene. 2000;19:4941–5.
Pasqualucci L, Migliazza A, Basso K, et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood. 2003;101:2914–23.
Wang X, Li Z, Naganuma A, et al. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci USA. 2002;99:15018–23.
Ohashi K, Miki T, Hirosawa S, et al. Characterization of the promoter region of human BCL-6 gene. Biochem Biophys Res Commun. 1995;214:461–7.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–82.
Bavi P, Uddin S, Ahmed M, et al. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am J Pathol. 2011;178:2109–20.
Gualco G, Bacchi LM, Domeny-Duarte P, et al. The contribution of HGAL/GCET2 in immunohistological algorithms: a comparative study in 424 cases of nodal diffuse large B-cell lymphoma. Mod Pathol. 2012;25:1439–45.
Jovanovic MP, Mihaljevic B, Jakovic L, et al. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes. J BUON. 2015;20:820–8.
Hideshima T, Mitsiades C, Ikeda H, et al. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010;115:3772–5.
Bhalla S, Evens AM, Dai B, et al. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood. 2011;118:1052–61.
Bernieh A, El Dinali M, Abulsayen H, et al. The incorporation of MEF2B in DLBCL immunostains algorithms: a tissue microarray comparative study. In Laboratory Investigation (Vol. 97, pp. 339A–339A) New York: Nature Publishing Group; 2017.